A Phase 2 Open-Label Study Of OSI-774 (NSC 718781) In Unresectable Hepatocellular Carcinoma
Phase of Trial: Phase II
Latest Information Update: 22 Jan 2013
At a glance
- Drugs Erlotinib (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 22 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 20 Feb 2007 Status changed from recruiting to completed
- 22 Aug 2005 New trial record.